Henrickson Nauta Wealth Advisors Inc. Lowers Position in Johnson & Johnson (NYSE:JNJ)

Henrickson Nauta Wealth Advisors Inc. cut its stake in Johnson & Johnson (NYSE:JNJ) by 10.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,461 shares of the company’s stock after selling 179 shares during the period. Henrickson Nauta Wealth Advisors Inc.’s holdings in Johnson & Johnson were worth $211,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Fiduciary Financial Group LLC lifted its holdings in shares of Johnson & Johnson by 5.8% during the fourth quarter. Fiduciary Financial Group LLC now owns 4,370 shares of the company’s stock valued at $621,000 after purchasing an additional 240 shares during the last quarter. Pacifica Partners Inc. lifted its holdings in shares of Johnson & Johnson by 17.1% during the fourth quarter. Pacifica Partners Inc. now owns 35,046 shares of the company’s stock valued at $5,047,000 after purchasing an additional 5,111 shares during the last quarter. Quad Cities Investment Group LLC lifted its holdings in shares of Johnson & Johnson by 6.4% during the fourth quarter. Quad Cities Investment Group LLC now owns 2,950 shares of the company’s stock valued at $427,000 after purchasing an additional 178 shares during the last quarter. 180 Wealth Advisors LLC lifted its holdings in shares of Johnson & Johnson by 7.1% during the fourth quarter. 180 Wealth Advisors LLC now owns 14,292 shares of the company’s stock valued at $2,067,000 after purchasing an additional 953 shares during the last quarter. Finally, Capital CS Group LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $204,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Citigroup lowered their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Bank of America restated a “neutral” rating and issued a $166.00 price objective on shares of Johnson & Johnson in a report on Tuesday, December 10th. Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective for the company. Finally, Royal Bank of Canada boosted their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.71.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.0 %

Shares of JNJ stock opened at $144.74 on Thursday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The firm has a fifty day moving average price of $149.12 and a 200-day moving average price of $156.09. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The company has a market cap of $348.48 billion, a price-to-earnings ratio of 20.95, a PEG ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter in the previous year, the company earned $2.66 EPS. Johnson & Johnson’s revenue for the quarter was up 5.2% on a year-over-year basis. As a group, equities analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.43%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.